Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ZTS Stock Forecast 2026-2027
$75.39
Current Price
$31.61B
Market Cap
Buy 11
Hold 9
Sell 0
Wall St Analyst Ratings
Distance to ZTS Price Targets
+112.2%
To High Target of $160.00
+48.6%
To Median Target of $112.00
+12.7%
To Low Target of $85.00
ZTS Price Momentum
-1.2%
1 Week Change
-5.3%
1 Month Change
-51.6%
1 Year Change
-40.1%
Year-to-Date Change
-53.0%
From 52W High of $160.48
+5.5%
From 52W Low of $71.47
📊 TOP ANALYST CALLS
Did ZTS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Zoetis is one of their latest high-conviction picks.
Latest ZTS Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, ZTS has a bullish consensus with a median price target of $112.00 (ranging from $85.00 to $160.00). The overall analyst rating is Buy (7.9/10). Currently trading at $75.39, the median forecast implies a 48.6% upside. This outlook is supported by 11 Buy, 9 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Glen Santangelo at Barclays, suggesting a 12.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZTS Analyst Ratings
11
Buy
9
Hold
0
Sell
ZTS Price Target Range
Low
$85.00
Average
$112.00
High
$160.00
Current: $75.39
Latest ZTS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZTS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 6, 2026 | HSBC | Rajesh Kumar | Buy | Maintains | $95.00 |
| Jul 1, 2026 | Barclays | Glen Santangelo | Equal-Weight | Maintains | $85.00 |
| Jun 30, 2026 | TD Cowen | Steve Scala | Buy | Maintains | $104.00 |
| Jun 26, 2026 | Stifel | Hold | Maintains | $N/A | |
| May 27, 2026 | Argus Research | Hold | Downgrade | $N/A | |
| May 22, 2026 | Stifel | Hold | Maintains | $N/A | |
| May 18, 2026 | Citigroup | Buy | Maintains | $N/A | |
| May 8, 2026 | UBS | Neutral | Maintains | $N/A | |
| May 8, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Apr 28, 2026 | UBS | Neutral | Maintains | $N/A | |
| Apr 15, 2026 | Citigroup | Buy | Initiates | $N/A | |
| Feb 13, 2026 | B of A Securities | Neutral | Maintains | $N/A | |
| Jan 22, 2026 | Piper Sandler | Neutral | Downgrade | $N/A | |
| Dec 9, 2025 | Barclays | Equal-Weight | Initiates | $N/A | |
| Dec 3, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Nov 21, 2025 | Keybanc | Sector Weight | Initiates | $N/A | |
| Nov 18, 2025 | Stifel | Hold | Maintains | $N/A | |
| Nov 12, 2025 | BTIG | Buy | Maintains | $N/A | |
| Nov 10, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Nov 5, 2025 | UBS | Neutral | Maintains | $N/A |
Zoetis Inc. (ZTS) Competitors
The following stocks are similar to Zoetis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zoetis Inc. (ZTS) Financial Data
Zoetis Inc. has a market capitalization of $31.61B with a P/E ratio of 12.4x. The company generates $9.53B in trailing twelve-month revenue with a 28.0% profit margin.
Revenue growth is +2.9% quarter-over-quarter, while maintaining an operating margin of +36.6% and return on equity of +67.7%.
Valuation Metrics
Market Cap
$31.61B
Enterprise Value
$38.99B
P/E Ratio
12.4x
PEG Ratio
17.5x
Price/Sales
3.3x
Growth & Margins
Revenue Growth (YoY)
+2.9%
Gross Margin
+71.7%
Operating Margin
+36.6%
Net Margin
+28.0%
EPS Growth
-0.2%
Financial Health
Cash/Price Ratio
+6.1%
Current Ratio
3.2x
Debt/Equity
286.2x
ROE
+67.7%
ROA
+15.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Zoetis Inc. (ZTS) Business Model
About Zoetis Inc.
What They Do
Global provider of animal health solutions.
Business Model
The company generates revenue by discovering, developing, and selling a wide range of animal health products, including medicines, vaccines, and diagnostics. It targets veterinarians, livestock producers, and pet owners, ensuring a diverse customer base that spans both companion animals and livestock.
Additional Information
Zoetis operates globally, with a strong presence in both the United States and international markets. Its product portfolio includes various therapeutic and preventative solutions, supported by advanced diagnostic tools and technologies, which enhance its value proposition in the animal health sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
14,500
CEO
Ms. Kristin C. Peck
Country
United States
IPO Year
2013
Website
www.zoetis.comZoetis Inc. (ZTS) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
ZTS Wins European Commission Approval for New Poultry Disease Vaccine
Zoetis wins EU approval for a single-dose poultry vaccine against Newcastle and Marek's diseases, expanding its vaccine portfolio and flock protection options.
Jul 08, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Quick Summary
Levi & Korsinsky, LLP notes discrepancies between Zoetis Inc.'s investor promises and actual performance, indicating potential compensation for shareholders who suffered losses between January 2025 and May 2026.
Why It Matters
Zoetis Inc.'s corrective disclosures indicate potential mismanagement or misinformation, impacting investor trust and stock performance, raising concerns about future earnings and liability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
ZTS Investors Have Opportunity to Lead Zoetis Inc. Securities Fraud Lawsuit with the Schall Law Firm
1 day ago
Quick Summary
A class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) for securities violations. Investors who bought shares between Jan 14, 2025, and May 6, 2026, should contact Schall Law Firm by July 27, 2026.
Why It Matters
The class action lawsuit against Zoetis may indicate potential legal and financial risks, affecting stock performance and investor sentiment during and after the litigation period.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) for alleged federal securities law violations during the period from January 14, 2025, to May 6, 2026.
Why It Matters
The class action lawsuit against Zoetis raises concerns over potential securities law violations, which may impact stock performance and investor confidence. Legal challenges can lead to financial liabilities.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) for alleged federal securities law violations during the period from January 14, 2025, to May 6, 2026.
Why It Matters
The class action lawsuit against Zoetis Inc. could signal potential financial liabilities and reputational damage, impacting stock performance and investor confidence in the company.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm reminds Zoetis Inc. (NYSE: ZTS) investors who purchased securities between Jan 14, 2025, and May 6, 2026, of a July 27, 2026, lead plaintiff deadline for potential compensation.
Why It Matters
The announcement indicates potential legal issues for Zoetis, which could impact stock performance and investor sentiment. Class action participation might affect shareholder compensation prospects.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) for alleged securities violations. Affected shareholders are urged to contact DJS Law Group for potential lead plaintiff roles.
Why It Matters
A class action lawsuit against Zoetis for securities violations could impact the company's stock price and investor confidence, potentially leading to financial losses for shareholders.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About ZTS Stock
What is Zoetis Inc.'s (ZTS) stock forecast for 2027?
Based on our analysis of 4 Wall Street analysts, Zoetis Inc. (ZTS) has a median price target of $112.00. The highest price target is $160.00 and the lowest is $85.00.
Is ZTS stock a good investment in 2027?
According to current analyst ratings, ZTS has 11 Buy ratings, 9 Hold ratings, and 0 Sell ratings. The stock is currently trading at $75.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZTS stock?
Wall Street analysts predict ZTS stock could reach $112.00 in the next 12 months. This represents a 48.6% increase from the current price of $75.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zoetis Inc.'s business model?
The company generates revenue by discovering, developing, and selling a wide range of animal health products, including medicines, vaccines, and diagnostics. It targets veterinarians, livestock producers, and pet owners, ensuring a diverse customer base that spans both companion animals and livestock.
What is the highest forecasted price for ZTS Zoetis Inc.?
The highest price target for ZTS is $160.00 from at , which represents a 112.2% increase from the current price of $75.39.
What is the lowest forecasted price for ZTS Zoetis Inc.?
The lowest price target for ZTS is $85.00 from Glen Santangelo at Barclays, which represents a 12.7% increase from the current price of $75.39.
What is the overall ZTS consensus from analysts for Zoetis Inc.?
The overall analyst consensus for ZTS is bullish. Out of 4 Wall Street analysts, 11 rate it as Buy, 9 as Hold, and 0 as Sell, with a median price target of $112.00.
How accurate are ZTS stock price projections?
Stock price projections, including those for Zoetis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 14, 2026 4:14 AM UTC